A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
Active, not recruiting · NCT06537310 · Registry updated 2026-10-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors | Cancer-Neoplasms | Active, not recruiting | Phase 1 | 2026-10-01 | NCT06537310 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hoffmann-La Roche | 280 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Austin Health | Heidelberg | Australia | 70 |
| BC Cancer ? Vancouver | Vancouver | Canada | 2 |
| Clinica Universidad de Navarra | Pamplona | Spain | 58 |
| Clinica Universidad de Navarra Madrid | Madrid | Spain | 8 |
| Fundacion Jimenez Diaz | Madrid | Spain | 12 |
| Kinghorn Cancer Centre | Darlinghurst | Australia | 11 |
| McGill University Health Center | Montreal | Canada | 27 |
| Princess Margaret Cancer Center | Toronto | Canada | 30 |
| Rigshospitalet | København Ø | Denmark | 22 |
| UZ Leuven Gasthuisberg | Leuven | Belgium | 33 |
| Vall d?Hebron Institute of Oncology (VHIO), Barcelona | Barcelona | Spain | 8 |